Thermo Fisher Scientific (NYSE:TMO) today posted third-quarter results that beat the overall consensus on Wall Street.
The Waltham, Massachusetts–based laboratory supply company reported profits of $1.9 billion, or $4.79 per share, on sales of $9.3 billion for the three months ended October 2, for a bottom-line loss of -1.6% on sales growth of 9.49% compared with Q3 2020.
Get the full story on our sister site, Medical Design & Outsourcing.
Filed Under: Drug Discovery, Medical Design & Outsourcing